Human Skeletal Myoblasts (HSkM)

Primary normal human skeletal myoblasts (HSkM) are designed to undergo highly efficient differentiation directly following plating of cryopreserved cells. Each vial contains cells that have been cryopreserved in a medium containing 10% DMSO and will differentiate within 48 hours after plating. These cells do not require expansion prior to differentiation. Cell viability is >70% post thaw with a ≥50% myogenic index after 48 hours. They are intended for use by researchers investigating the molecular and biochemical bases of various normal and disease processes. They are compatible with Bacmam delivery technologies for various downstream applications. Large size contains 4.5 x 10^6–7.5 x 10^6 cells per vial and small size contains 1.1 x 10^6–1.9 x 10^6 cells per vial.

The cells are:

• Performance tested—guaranteed to differentiate ≥50% following 48 hours of incubation
• Guaranteed to be ≥70% viable
• Tested for mycoplasma, bacteria, yeast or other fungi, hepatitis B, hepatitis C, and HIV-1 viruses

Each vial contain sufficient number of cells to fully seed a single multi-well dish (ranging in format from 6-well to 384-well).